Area of research
Pharmacology · Genetics
Research interest
Research interests include Tamoxifen, Breast cancer, Medicine, CYP2D6, Oncology, and Cancer research.
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Feasibility of Patient-Derived 3D Gastrointestinal Stromal Tumour Models as Alternatives for In Vivo Mouse Models
Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCC
Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort
Cross‐Ancestry Genome‐Wide Association Study Defines the Extended <scp><i>CYP2D6</i></scp> Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations
Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
Pharmacologic Targeting of MMP2/9 Decreases Peritoneal Metastasis Formation of Colorectal Cancer in a Human Ex Vivo Peritoneum Culture Model
(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients
Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
The Influences of Adherence to Tamoxifen and <i>CYP2D6</i> Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
Abstract 3425: Exome-sequencing derived mutations of endocrine treated ER-positive early breast cancer
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes
Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS